Sign in

Myeloproliferative neoplasms

Current status: Treatable, not yet curable

A group of slow-growing diseases in which the bone marrow makes too many red blood cells, white blood cells or platelets. Too many red blood cells make the blood thick, and extra blood cells can make clots form, which can raise the risk of stroke or heart attack. For polycythaemia vera, treatment can include removing some blood, daily low-dose aspirin, or medicines such as hydroxycarbamide that lower the number of red blood cells. Polycythaemia vera, one of the main types, usually starts later in life, on average at 60.

Read more about myeloproliferative neoplasms
Where research stands todayUpdated 18 Nov 2026

Trial-stage treatments and research studies you can joinOpen trials for referral

Registry data only. Frontlight does not judge whether a patient can take part: the trial team decides.

Filters

Country
City
Distance is calculated in your browser. Your city is not sent to us.
Type
Get notified of new trialsLatvia, all cities, all phases
Your ageShows only trials that take people your age.
Phase

Search the publications

The results open on the publications page in a new tab, so this page stays as it is.

Lists with this disease filtered

Where treatment stands

One EU-listed medicine, momelotinib, got its first EU authorisation in January 2024.

Approved: 12

Officially approved for this disease in the EU, the US, Switzerland or France.

Human testing stage: 14

Being tested in people. Many treatments at this stage are never approved.

Animal testing stage: 2

Worked in animals in a study published in the last 12 months. Most treatments at this stage never reach people.

Support organisations

Patient organisations and helplines in Latvia, for you and your family.

We have no organisations for this disease listed in Latvia yet. General support there is below.

General support in Latvia

  • Vienotais krīzes tālrunis 116123

    Latvia's toll-free 24/7 emotional support and crisis line 116123, published by the National Health Service.

  • Nacionālais veselības dienests (NVD)

    Latvia's National Health Service, which administers state-funded healthcare and informs residents about services via a free information line.

International organisations

  • MPN Advocacy & Education International

    Nonprofit providing education and advocacy for people living with myeloproliferative neoplasms.

  • MPN Research Foundation

    Foundation funding research into myeloproliferative neoplasms and supporting the MPN patient community.

Frontlight Community

Myeloproliferative neoplasms community in Latvia

People living with myeloproliferative neoplasms and those close to them share what they went through. Posts are not medical advice: ask your doctor about your own treatment.

Offer tissue or data

There are three ways to help research move faster.

Give tissue or bloodA biobank stores your sample so many research teams can use it.No open programme yet
Share your health dataA patient registry collects your health data, without your name, for research.How to join
Take part as a healthy volunteerStudies also need people without the disease, for comparison. Family and friends can help.Volunteer

Approved treatments

13 medicines are approved for myeloproliferative neoplasms in at least one of the places we checked. An approval in one place does not mean the medicine is offered or paid for where you live.

Checked on 18 Nov 2026 in the official lists of the US (FDA), the EU (European Commission and EMA) and Switzerland (Swissmedic), which we read every day. The lists of Japan (PMDA, approvals since April 2004), France (ANSM, medicines approved in France only) and Taiwan (TFDA) were checked on 11 Nov 2026. For Canada (Health Canada) and Singapore (HSA) we checked only whether a medicine is sold there, not what for. The French ratings are the opinions of the HAS Transparency Committee, from the French public medicines database (base de données publique des médicaments, newest opinion 10 Dec 2025). 1 uncertain match is left out. Other countries' own approvals were not checked.

“Miracle cure” fact checker

Social media spreads misinformation. Paste here what you read, and we'll tell you whether there is scientific evidence behind it.

What you paste is checked with AI (Anthropic, USA) and is not stored. Please leave out names and other personal details.

Before you pay for anything, ask three things

  1. Is there a published study in people?
  2. Can I have the full price in writing?
  3. What does my doctor say?

About myeloproliferative neoplasms

Sources: NCI PDQ, NHS, Cancer Research UK, Blood

A group of slow-growing diseases in which the bone marrow makes too many red blood cells, white blood cells or platelets. Too many red blood cells make the blood thick, and extra blood cells can make clots form, which can raise the risk of stroke or heart attack. For polycythaemia vera, treatment can include removing some blood, daily low-dose aspirin, or medicines such as hydroxycarbamide that lower the number of red blood cells. Polycythaemia vera, one of the main types, usually starts later in life, on average at 60.

What is it?

Myeloproliferative neoplasms (MPNs) are a group of diseases in which the bone marrow makes too many red blood cells, white blood cells or platelets. Usually one kind of cell is affected most. The main types are polycythaemia vera (too many red cells), essential thrombocythaemia (too many platelets) and primary myelofibrosis (the marrow becomes scarred). Chronic myeloid leukaemia also belongs to this group but is described on its own page.

Many people have a change in a gene such as JAK2, CALR or MPL in their marrow cells. In polycythaemia vera, a JAK2 change usually causes the disease, and it is not usually inherited. Polycythaemia vera mostly starts later in life: the average age at diagnosis is 60.

The first signs

Some people have no signs at first, for example with polycythaemia vera, essential thrombocythaemia or myelofibrosis.

  • headaches, dizziness, or changes in vision;
  • itching, especially after a warm bath or shower;
  • a red face, or red, warm, burning or tingling hands and feet;
  • fullness or pain under the left ribs;
  • tiredness, night sweats, or losing weight without trying.

How doctors find out

A blood test counts your blood cells. Your family doctor may then send you to a blood specialist (haematologist). More blood tests look for the changed JAK2, CALR or MPL gene, and a bone marrow sample, taken with a needle, is checked in a lab.

Current treatment

Treatment depends on the type: for polycythaemia vera, removing blood, low-dose aspirin and hydroxyurea; for essential thrombocythaemia, hydroxyurea or interferon; for myelofibrosis, ruxolitinib or a donor stem cell transplant for some people.

Will it get worse?

Usually slowly, and some cases, particularly polycythaemia vera, need long-term treatment. People with polycythaemia vera may live slightly less long than average, because of the higher risk of heart attack and stroke. Over time, polycythaemia vera can lead to scarring of the marrow (myelofibrosis), and sometimes an MPN can turn into acute leukaemia. In myelofibrosis, how it goes depends on age, blood counts, immature cells in the blood, chromosome changes and symptoms such as fever or weight loss.

Medicines: what helps, and what to watch for

Treatment aims to prevent symptoms and problems such as blood clots. In polycythaemia vera, blood is removed regularly (venesection), about half a litre at a time, like giving blood: often weekly at first, then less often. Low-dose aspirin helps prevent clots. Medicines such as hydroxycarbamide or interferon can lower the number of red blood cells. Ruxolitinib, a targeted medicine, can ease symptoms such as tiredness, night sweats and weight loss in myelofibrosis, and is used in polycythaemia vera if chemotherapy does not work. Some people under 60 with essential thrombocythaemia and no symptoms only need regular checks.

Good to know:

  • Interferon is an injection 1 to 3 times a week that you can learn to give yourself, and it can be used in pregnancy; it can cause flu-like symptoms and hair loss;
  • In myelofibrosis, anaemia may need blood transfusions or other medicines.

A healthy lifestyle helps too

Healthy lifestyle changes can lower the risk of blood clots. Being overweight or smoking raises the risk, so losing weight and stopping smoking can help.

Surgery, radiotherapy or a transplant, for some people

In myelofibrosis, an enlarged spleen can be removed with surgery or treated with radiotherapy. For some people with myelofibrosis, a stem cell or bone marrow transplant from a donor is an option: strong chemotherapy is followed by healthy blood-forming cells.

Is there a cure?

Treatment usually aims to control the symptoms, not to cure the condition. A bone marrow or stem cell transplant from a donor aims to cure it. It is not suitable for everyone, because it is an intensive treatment with many risks.

See the 239 trials you can join

Median survival

About 20 years in essential thrombocythemia, 13.5 years in polycythemia vera and 6 years in primary myelofibrosis

Measured in: Patients with essential thrombocythemia, polycythemia vera or primary myelofibrosis from the Mayo Clinic (826 patients)

The figures behind it

Mayo Clinic patients (826, 58% followed until death): median survival 19.8 years in essential thrombocythemia (292 patients), 13.5 years in polycythemia vera (267) and 5.9 years in primary myelofibrosis (267). In primary myelofibrosis (428 Mayo and Italian patients) the median was 16 years with a CALR mutation and 2.3 years in triple-negative patients.